BAD Antibody - #AF6472
| Product: | BAD Antibody |
| Catalog: | AF6472 |
| Description: | Rabbit polyclonal antibody to BAD |
| Application: | WB IHC IF/ICC |
| Reactivity: | Human, Mouse, Rat |
| Prediction: | Bovine, Horse, Sheep, Dog |
| Mol.Wt.: | 23kDa; 18kD(Calculated). |
| Uniprot: | Q92934 |
| RRID: | AB_2835291 |
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# AF6472, RRID:AB_2835291.
Fold/Unfold
AI325008; BAD; BAD_HUMAN; BBC 2; BBC2; BBC6; Bcl 2 Antagonist of Cell Death; Bcl 2 Binding Component 6; BCL X / BCL 2 Binding Protein; BCL X Binding Protein; Bcl XL/Bcl 2 Associated Death Promoter; Bcl-2-binding component 6; Bcl-2-like protein 8; Bcl-XL/Bcl-2-associated death promoter; Bcl2 antagonist of cell death; BCL2 antagonist of cell death protein; BCL2 associated agonist of cell death; Bcl2 Associated Death Promoter; BCL2 binding component 6; BCL2 binding protein; Bcl2 Like 8 Protein; Bcl2-L-8; BCL2L8; Proapoptotic BH3 Only Protein;
Immunogens
- Q92934 BAD_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQEQPTSSSHHGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSWWDRNLGRGSSAPSQ
Predictions
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - Q92934 As Substrate
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| M1 | Acetylation | Uniprot | |
| S25 | Phosphorylation | Uniprot | |
| S32 | Phosphorylation | Uniprot | |
| S34 | Phosphorylation | Uniprot | |
| K36 | Acetylation | Uniprot | |
| S71 | Phosphorylation | Uniprot | |
| S74 | Phosphorylation | Q13153 (PAK1) | Uniprot |
| S75 | Phosphorylation | Q9NQU5 (PAK6) , Q15349 (RPS6KA2) , Q9P1W9 (PIM2) , P31749 (AKT1) , P22612 (PRKACG) , P28482 (MAPK1) , P27361 (MAPK3) , O75582 (RPS6KA5) , Q04759 (PRKCQ) , Q13153 (PAK1) , P04049 (RAF1) , P41743 (PRKCI) , Q15418 (RPS6KA1) , P45983 (MAPK8) , Q02156 (PRKCE) , Q86V86 (PIM3) , Q15139 (PRKD1) , P17612 (PRKACA) , P22694 (PRKACB) , P51812 (RPS6KA3) , P11309 (PIM1) , O96013 (PAK4) , P15056 (BRAF) , P10398 (ARAF) | Uniprot |
| Y76 | Phosphorylation | Uniprot | |
| T80 | Phosphorylation | Uniprot | |
| S91 | Phosphorylation | P06493 (CDK1) , P45983 (MAPK8) | Uniprot |
| R94 | Methylation | Uniprot | |
| R96 | Methylation | Uniprot | |
| S97 | Phosphorylation | Uniprot | |
| S99 | Phosphorylation | Q9Y243 (AKT3) , P51812 (RPS6KA3) , Q04759 (PRKCQ) , Q13153 (PAK1) , P31751 (AKT2) , Q15139 (PRKD1) , P41743 (PRKCI) , P31749 (AKT1) , P15056 (BRAF) , P04049 (RAF1) , Q15418 (RPS6KA1) , Q86V86 (PIM3) , P23443 (RPS6KB1) , P17612 (PRKACA) , Q9P1W9 (PIM2) , Q02156 (PRKCE) , P11309 (PIM1) , P10398 (ARAF) , P22612 (PRKACG) , P22694 (PRKACB) | Uniprot |
| Y110 | Phosphorylation | Uniprot | |
| S118 | Phosphorylation | Q15139 (PRKD1) , Q02156 (PRKCE) , P31751 (AKT2) , Q13153 (PAK1) , Q86V86 (PIM3) , P17612 (PRKACA) , Q9P1W9 (PIM2) , P15056 (BRAF) , Q9Y243 (AKT3) , Q15349 (RPS6KA2) , P31749 (AKT1) , Q13976 (PRKG1) , P11309 (PIM1) , P10398 (ARAF) , P04049 (RAF1) , P22612 (PRKACG) , P22694 (PRKACB) , P41743 (PRKCI) , Q15418 (RPS6KA1) | Uniprot |
| S124 | Phosphorylation | Uniprot | |
| S128 | Phosphorylation | Uniprot | |
| S134 | Phosphorylation | Q13153 (PAK1) , P15056 (BRAF) , Q13555 (CAMK2G) | Uniprot |
| T137 | Phosphorylation | Uniprot | |
| T139 | Phosphorylation | Uniprot | |
| S146 | Phosphorylation | Uniprot | |
| S153 | Phosphorylation | P17612 (PRKACA) , O75582 (RPS6KA5) , Q15418 (RPS6KA1) | Uniprot |
| R161 | Methylation | Uniprot |
Research Backgrounds
Promotes cell death. Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX. Can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2 (By similarity). Appears to act as a link between growth factor receptor signaling and the apoptotic pathways.
Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 and Ser-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotes heterodimerization with 14-3-3 proteins. This interaction then facilitates the phosphorylation at Ser-118, a site within the BH3 motif, leading to the release of Bcl-X(L) and the promotion of cell survival. Ser-99 is the major site of AKT/PKB phosphorylation, Ser-118 the major site of protein kinase A (CAPK) phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almost completely blocked by the apoptotic C-terminus cleavage product of PKN2 generated by caspases-3 activity during apoptosis.
Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99.
Mitochondrion outer membrane. Cytoplasm.
Note: Colocalizes with HIF3A in the cytoplasm (By similarity). Upon phosphorylation, locates to the cytoplasm.
Expressed in a wide variety of tissues.
Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity). The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (By similarity). Interacts with AKT1 and PIM3. Interacts (via BH3 domain) with NOL3 (via CARD domain); preventing the association of BAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BAD and BAX (By similarity). Interacts with GIMAP3/IAN4 and GIMAP5/IAN5.
Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX for their pro-apoptotic activity and for their interaction with anti-apoptotic members of the Bcl-2 family.
Belongs to the Bcl-2 family.
Research Fields
· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)
· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)
· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)
· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)
· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.
· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.
· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).
· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.
· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.
· Human Diseases > Infectious diseases: Viral > Hepatitis C.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Viral carcinogenesis.
· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Renal cell carcinoma. (View pathway)
· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)
· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)
· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)
· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)
· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.